NCT06761287 Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer
| NCT ID | NCT06761287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire Saint Pierre |
| Condition | Locally Advanced Rectal Cancer (LARC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-03-28 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-03-28 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This interventional, non-randomized, prospective trial aims to evaluate the role of endoscopic resection following neoadjuvant treatment in patients with locally advanced rectal cancer. Phase I focuses on assessing the feasibility, safety and efficacy of endoscopic resection of residual scar or superficial residual neoplastic tissue following neoadjuvant treatment. Phase II explores the potential of this approach to guide patient selection for total mesorectal excision and to serve as a definitive treatment option for those with limited residual disease.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years old * Signed informed consent * Patients diagnosed with locally advanced rectal cancer showing complete or near-complete clinical response after neoadjuvant therapy without evidence of invasive disease (\>T2) or locoregional invasion on magnetic resonance imaging and without any signs of metastatic disease on a computerized tomography scan. * Patients diagnosed with locally advanced rectal cancer showing incomplete response with presence of superficial residual lesions, without invasive features on endoscopic evaluation, without evidence of invasive disease (\>T2) or locoregional invasion on magnetic resonance imaging and without any signs of metastatic disease on a computerized tomography scan. * Without previous medical history of rectal cancer or rectal surgery Exclusion Criteria: * Previous medical history of rectal cancer * Previous rectal surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06761287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Rectal Cancer (LARC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06761287 currently recruiting?
Yes, NCT06761287 is actively recruiting participants. Contact the research team at mariana.figueiredo@stpierre-bru.be for enrollment information.
Where is the NCT06761287 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06761287 clinical trial?
NCT06761287 is sponsored by Centre Hospitalier Universitaire Saint Pierre. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.